China · Delayed Price · Currency is CNY Sansure Biotech Statistics
Total Valuation
Sansure Biotech has a market cap or net worth of CNY 10.40 billion. The enterprise value is 7.73 billion.
| Market Cap | 10.40B |
| Enterprise Value | 7.73B |
Important Dates
The last earnings date was Thursday, April 30, 2026.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Sansure Biotech has 574.18 million shares outstanding. The number of shares has increased by 2.08% in one year.
| Current Share Class | 574.18M |
| Shares Outstanding | 574.18M |
| Shares Change (YoY) | +2.08% |
| Shares Change (QoQ) | +3.42% |
| Owned by Insiders (%) | 39.93% |
| Owned by Institutions (%) | 12.54% |
| Float | 292.89M |
Valuation Ratios
The trailing PE ratio is 68.95 and the forward PE ratio is 36.98.
| PE Ratio | 68.95 |
| Forward PE | 36.98 |
| PS Ratio | 6.49 |
| PB Ratio | 1.44 |
| P/TBV Ratio | 1.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 47.99 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.92, with an EV/FCF ratio of -47.05.
| EV / Earnings | 49.24 |
| EV / Sales | 4.82 |
| EV / EBITDA | 19.92 |
| EV / EBIT | 47.39 |
| EV / FCF | -47.05 |
Financial Position
The company has a current ratio of 4.26, with a Debt / Equity ratio of 0.16.
| Current Ratio | 4.26 |
| Quick Ratio | 3.83 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 2.99 |
| Debt / FCF | -7.19 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 1.57% and return on invested capital (ROIC) is 3.56%.
| Return on Equity (ROE) | 1.57% |
| Return on Assets (ROA) | 1.10% |
| Return on Invested Capital (ROIC) | 3.56% |
| Return on Capital Employed (ROCE) | 2.03% |
| Weighted Average Cost of Capital (WACC) | 6.51% |
| Revenue Per Employee | 683,457 |
| Profits Per Employee | 66,897 |
| Employee Count | 2,409 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.00 |
Taxes
In the past 12 months, Sansure Biotech has paid 11.97 million in taxes.
| Income Tax | 11.97M |
| Effective Tax Rate | 9.42% |
Stock Price Statistics
The stock price has decreased by -10.06% in the last 52 weeks. The beta is 0.55, so Sansure Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -10.06% |
| 50-Day Moving Average | 18.20 |
| 200-Day Moving Average | 20.10 |
| Relative Strength Index (RSI) | 53.20 |
| Average Volume (20 Days) | 3,795,546 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sansure Biotech had revenue of CNY 1.60 billion and earned 156.94 million in profits. Earnings per share was 0.26.
| Revenue | 1.60B |
| Gross Profit | 1.20B |
| Operating Income | 170.42M |
| Pretax Income | 127.05M |
| Net Income | 156.94M |
| EBITDA | 389.99M |
| EBIT | 170.42M |
| Earnings Per Share (EPS) | 0.26 |
Balance Sheet
The company has 3.92 billion in cash and 1.18 billion in debt, with a net cash position of 2.74 billion or 4.78 per share.
| Cash & Cash Equivalents | 3.92B |
| Total Debt | 1.18B |
| Net Cash | 2.74B |
| Net Cash Per Share | 4.78 |
| Equity (Book Value) | 7.23B |
| Book Value Per Share | 11.52 |
| Working Capital | 3.95B |
Cash Flow
In the last 12 months, operating cash flow was 216.81 million and capital expenditures -381.04 million, giving a free cash flow of -164.22 million.
| Operating Cash Flow | 216.81M |
| Capital Expenditures | -381.04M |
| Depreciation & Amortization | 219.57M |
| Net Borrowing | 329.34M |
| Free Cash Flow | -164.22M |
| FCF Per Share | -0.29 |
Margins
Gross margin is 74.84%, with operating and profit margins of 10.63% and 9.79%.
| Gross Margin | 74.84% |
| Operating Margin | 10.63% |
| Pretax Margin | 7.92% |
| Profit Margin | 9.79% |
| EBITDA Margin | 24.32% |
| EBIT Margin | 10.63% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.54, which amounts to a dividend yield of 3.08%.
| Dividend Per Share | 0.54 |
| Dividend Yield | 3.08% |
| Dividend Growth (YoY) | -24.60% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 213.41% |
| Buyback Yield | -2.08% |
| Shareholder Yield | 1.04% |
| Earnings Yield | 1.51% |
| FCF Yield | -1.58% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.48.
| Last Split Date | Jun 1, 2022 |
| Split Type | Forward |
| Split Ratio | 1.48 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |